机构：[1]Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China[2]Department ofHematology, General Hospital of Kunming Military Region of PLA, Kunming, China[3]Department of Hematology,Affiliated Hospital of Guizhou Medical University, Guiyang, China[4]Department of Hematology, Tangdu Hospital,Forth Military Medical University, Xi’an, China[5]Department of Hematology, General Hospital of Chengdu MilitaryRegion of PLA, Chengdu, Sichuan, China[6]Department of Hematology, First Yunnan Provincial People’s Hospital,Kunming, China[7]Department of Hematology, Affiliated Hospital of Kunming Medical College, Kunming, China[8]Department of Health Statistics, College of Military Preventive Medicine, Third Military Medical University,Chongqing, China
HLA-haploidentical hematopoietic stem cell transplantation (HSCT) may be an option for severe aplastic anemia (SAA) patients. However, to date, no large-sample studies have been performed to determine which types of SAA patients are suitable for HLA-haploidentical HSCT. We retrospectively studied 189 consecutive patients with SAA who underwent HLA-identical or HLA-haploidentical HSCT at seven transplant centers in China. Propensity score matching (PSM) was applied in this study to reduce the influence of potential confounders. The 5-year overall survival (OS) rate was 72.0% in the HLA-haploidentical group and 76.5% in the HLA-identical group. The median time to achieve engraftment and the incidence of acute GVHD/chronic GVHD were not significantly different between the two groups. In the subgroup analysis, the outcome of patients older than 40 years in the HLA-haploidentical group was significantly poorer than that of patients younger than 40 years in the same group and that of patients older than 40 years in the HLA-identical group. Based on the above results, we suggest that HLA-haploidentical relative HSCT should be considered as a valid alternative option for patients younger than 40 years with SAA for whom no matched sibling donor is available.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|3 区综合性期刊
小类|3 区综合性期刊
最新[2023]版：
大类|2 区综合性期刊
小类|2 区综合性期刊
第一作者：
第一作者机构：[1]Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Yunjing Zeng,Sanbin Wang,Jishi Wang,et al.Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China.[J].Scientific reports.2018,8(1):2479.doi:10.1038/s41598-018-20853-9.
APA：
Yunjing Zeng,Sanbin Wang,Jishi Wang,Li Liu,Yi Su...&Xi Zhang.(2018).Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China..Scientific reports,8,(1)
MLA：
Yunjing Zeng,et al."Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China.".Scientific reports 8..1(2018):2479
